Salah satu analgetik golongan cox-2 inhibitor adalah

Salah satu analgetik golongan cox-2 inhibitor adalah

1.
Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase: A new avenue in anti-inflammatory therapy.


Biochem. Pharmacol.
2001;62:1433–1438.

[PubMed]
[Google Scholar]

2.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.


Nature.
1971;231

[PubMed]
[Google Scholar]

3.
Smith WL, Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and 2.


Prostaglandins and other Lipid Mediators.
2002;68-69:115–128.

[PubMed]
[Google Scholar]

4.
HataAN , Breyer RM. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation.


Pharmacol. Ther.
2004;103:147–166.

[PubMed]
[Google Scholar]

5.
Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs.


Pharmacol. Res.
2005;51:85–94.

[PubMed]
[Google Scholar]

6.
Smith WL, MarnettLJ Prostaglandinendoperoxide synthase: structure and catalysis.


Biochim. Biophys. Acta.
1991;1083:1–17.

[PubMed]
[Google Scholar]

7.
Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date.


Med. Res. Rev.
1996;16:181–206.

[PubMed]
[Google Scholar]

8.
Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2.


Annu. Rev. Pharmacol. Toxicol.
1998;38:97–120.

[PubMed]
[Google Scholar]

9.
Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs.


Eur. J. Med. Chem.
2003;38:645–659.

[PubMed]
[Google Scholar]

10.
Dannhardt G, Kiefer W. Cyclooxygenase inhibitors-currunt status and future prospects.


Eur. J. Med. Chem.
2001;36:109–126.

[PubMed]
[Google Scholar]

11.
Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets.


Trends Mol. Med.
2002;8:390–396.

[PubMed]
[Google Scholar]

12.
Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.


J. Biol. Chem.
1990;265:16737–16740.

[PubMed]
[Google Scholar]

13.
Tazawa R, Xa XM, Wu KK, Wang LH. Biochemical characterization of the genomic structure, chromosomal location and promoter of human prostaglandin h synthase-2 gene.


Biophys. Res. Commun.
1994;203:190–199.

[PubMed]
[Google Scholar]

14.
Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am.


J. Physiol.
1996;270:G393–400.

[PubMed]
[Google Scholar]

15.
Konturek PC, Kania J, Burnat G, Hahn EG, Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.


J. Physiol. Pharmacol.
2005;56:S57–73.

[PubMed]
[Google Scholar]

16.
Yamagata K, Andreasson KA, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids.


Neuron.
1993;11:371–386.

[PubMed]
[Google Scholar]

17.
Ferreri NR, An SJ, McGiff JC. Cyclooxygenase-2 expression and function in the medullary thick ascending limb.


Am. J. Physiol.
1999;277:F360–F368.

[PubMed]
[Google Scholar]

18.
Kniss DA. Cyclooxygenases in reproductive medicine and biology – The role of estradiol and progesterone.


J. Soc. Gynecol. Invest.
1999;6:285–292.

[PubMed]
[Google Scholar]

19.
Garavito RM, Malkowski MG, Dewitt DL. The structures of prostaglandin endoperoxide H synthases-1 and -2.


Prostaglandins and other Lipid Mediators.
2002;68-69:129–152.

[PubMed]
[Google Scholar]

20.
Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1.


Nature.
1994;367:243–249.

[PubMed]
[Google Scholar]

21.
Kurumbail RG, Kiefer JR, Marnett LJ. Cyclooxygenase enzymes: Catalysis and inhibition.


Curr. Opin. Struct. Biol.
2001;11:752–760.

[PubMed]
[Google Scholar]

22.
Loll PJ, Picot D, Garavito RM. Nat.


Struct. Biol.
1995;2:637–643.

[PubMed]
[Google Scholar]

23.
Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.


Nature.
1996;384:644–648.

[PubMed]
[Google Scholar]

24.
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. From the cover: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression.


Proc. Natl. Acad. Sci. USA.
2002;99:13926–13931.

[PMC free article]
[PubMed]
[Google Scholar]

25.
Shaftel S, Olschowka J, Hurley S, Moore A, O’Banion M. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells.


Brain. Res. Mol. Brain. Res.
2003;119:213–215.

[PubMed]
[Google Scholar]

26.
Schwab JM, Schluesener HJ, Meyermann R, Serhan CN. COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics.


Prostaglandins Leukotrienes and Essential Fatty Acids.
2003;69:339–343.

[PubMed]
[Google Scholar]

27.
Simmons D. Variants of cyclooxygenase-1 and their roles in medicine.


Thromb. Res.
2003;110:265–268.

[PubMed]
[Google Scholar]

28.
Botting R. COX-1 and COX-3 inhibitors.


Thromb. Res.
2003;110:269–272.

[PubMed]
[Google Scholar]

29.
Dinchuk J, Liu R, Trzaskos J. COX-3: In the wrong frame in mind.


J. Immunol. Lett.
2003;86:121.

[PubMed]
[Google Scholar]

30.
Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition.


Brain. Res. Rev.
2005;48:352–329.

[PubMed]
[Google Scholar]

31.
Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal.


Pharmacol. Res.
2001;44:437–450.

[PubMed]
[Google Scholar]

32.
Morham SG, Langenbach R, Loftin CD, TianoHF , Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA. Prostaglandin synthase 2 gene disruptions causes severe renal pathology in the mouse.


Cell.
1995;83:473–482.

[PubMed]
[Google Scholar]

33.
Chakraborty I, Das SK, Wang J, Dey SK. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids.


J. Mol. Endocrinol.
1996;16:107–122.

[PubMed]
[Google Scholar]

Baca Juga :   Tuliskan 2 gerakan senam lantai yang mengandung unsur keseimbangan berpindah dan tolakan

34.
Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J.


Rheumatol.
2001;28:2375–2382.

[PubMed]
[Google Scholar]

35.
Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.


Trends. Pharmacol. Sci.
2003;24:245–252.

[PubMed]
[Google Scholar]

36.
FitzGerald GA. Coxibs and cardiovascular disease.


N. Engl. J. Med.
2004;351:1709–1711.

[PubMed]
[Google Scholar]

37.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothromosis? Meta-analysis of randomised trials.


Br. Med. J.
2006;332:1302–1308.

[PMC free article]
[PubMed]
[Google Scholar]

38.
Chakraborti AK, Garg SK, Kumar R, Motiwala HF, Jadhavar PS. Progress in COX-2 inhibitors: A journey so far.


Curr. Med.Chem.
2010;17:1563–1593.

[PubMed]
[Google Scholar]

39.
Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in-vivo and ex-vivo: implications for therapy with platelet inhibitory drugs.


Blood.
1987;69:180–86.

[PubMed]
[Google Scholar]

40.
Ritter JM, Harding I, Warren JB. Precaution, cyclooxygenase inhibition and cardiovascular risk.


Trends Pharmcol. Sci.
2009;30:503–508.

[PubMed]
[Google Scholar]

41.
Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase: A new avenue in anti-inflammatory therapy?


Biochem. Pharmacol.
2001;62:1433–1438.

[PubMed]
[Google Scholar]

42.
Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Cyclooxygenase-2 as a target for anticancer drug development.


Crit. Rev. Oncol. Hematol.
2006;59:51–64.

[PubMed]
[Google Scholar]

43.
Dannenberg AJ. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.


Lancet Oncol.
2001;2:544–551.

[PubMed]
[Google Scholar]

44.
Shao J, Sheng H, Inoue H, Morrow JD, Dubois RN. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells.


J. Biol. Chem.
2000;275:33951–33956.

[PubMed]
[Google Scholar]

45.
Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression: the role of the 3′-untranslated region.


J. Biol. Chem.
2000;275:11750–11757.

[PubMed]
[Google Scholar]

46.
Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment.


Trends Pharmacol. Sci.
2003;2:96–101.

[PubMed]
[Google Scholar]

47.
Eling TE, Thompson DC, Foureman GL, Curtis JF, Hughes MF. Prostaglandin H synthase and xenobitic oxidation.


Annu. Rev. Pharmacol. Toxicol.
1990;30:1–45.

[PubMed]
[Google Scholar]

48.
Wiese FW, Thompson PA, Kadlubar FF. Carcinogen substrate specificity of human COX-1 and COX-2.


Carcinogenesis.
2001;22:5–10.

[PubMed]
[Google Scholar]

49.
Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.


Cancer Res.
2002;62:2029–2033.

[PubMed]
[Google Scholar]

50.
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy.


Nat. Med.
2002;8:289–293.

[PubMed]
[Google Scholar]

51.
Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.


J. Clin. Oncol.
2005;23:254–266.

[PubMed]
[Google Scholar]

52.
Wang D, Mann JR, Dubois RN. The Role of prostaglandins and other eicosanoids in the gastrointestinal tract.


Gastroenterology.
2005;128:1445–1461.

[PubMed]
[Google Scholar]

53.
Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores JG. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells.


Hepatology.
2002;35:552–559.

[PubMed]
[Google Scholar]

54.
Battu S, Rigaud M, Beneytout JL. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL19A.


Anticancer Res.
1998;18:3579–3583.

[PubMed]
[Google Scholar]

55.
Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer.


Crit. Rev. Oncol. Hematol.
2004;52:81–101.

[PubMed]
[Google Scholar]

56.
Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.
Proc. Natl. Acad. Sci. USA (1997;94:3336–3340.
[PMC free article]
[PubMed]
[Google Scholar]

57.
Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC, Dubinett SM. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.


J. Immunol.
2000;164:361–370.

[PubMed]
[Google Scholar]

58.
Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype.


Curr. Pharm. Des.
2004;10:647–657.

[PubMed]
[Google Scholar]

59.
McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies.


Neurobiol. Aging.
2007;28:639–647.

[PubMed]
[Google Scholar]

60.
Aisen PS. Evaluation of selective COX-e inhibitors for the treatment of Alzheimer’s disease.


J. Pain Symp. Manage.
2002;23:s35–40.

[PubMed]
[Google Scholar]

61.
Asanuma M, Miyazaki I. Nonsteriodal anti-inflammatory drugs in experimental Parkinsonian models and Parkinson’s disease.


Curr. Pharm. Des.
2008;14:1428–34.

[PubMed]
[Google Scholar]

62.
Singh SK, Vobbalareddy S, Shivaramakrishna S, Krishnamaraju A, Abdul Rajjak S, Casturi SR, Akhila V, Rao YK. Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors.


Bioorg. Med. Chem. Lett.
2004;14:1683–1688.

[PubMed]
[Google Scholar]

63.
Friesen RW, Dube´ D, Fortin R, Frenette R, Prescott S, Cromlish W, Greig GM, Kargman S, Wong E, Chan CC, Gordon R, Xu L, Riendeau D. Novel 1,2-diarylcyclobutenes: Selective and orally active COX-2 inhibitors.


Bioorg. Med. Chem. Lett.
1996;6:2677–2682.

[Google Scholar]

Baca Juga :   Salah satu bentuk interaksi yang baik antara manusia dan lingkungan adalah brainly

64.
Biava M, Porretta GC, Poce G, Supino S, Forli S, Rovini M, Cappelli A, Manetti F, BottaM , SautebinL , Rossi A, Pargola C, Ghelardini C, VivoliE , Makovec F, Anzellotti P, Patrignani P, AnziniM Cyclooxygenase-2 inhibitors: 1,5- diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase- 2/cyclooxygenase-1 selectivity.


J. Med. Chem.
2007;50:5403–11.

[PubMed]
[Google Scholar]

65.
Singh SK, Reddy PG, Rao KS, Lohray BB, Misra P, Rajjak SA, Rao YK, Venkateswarlu A. Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5- diarylpyrazole class of COX-2 inhibitors.


Bioorg. Med. Chem. Lett.
2004;14:499–504.

[PubMed]
[Google Scholar]

66.
Carter JS, Kramer S, Talley JJ, Penning T, Collins P, Graneto M J, Seibert K, Koboldt CM, Masferrer J, Zweifel B. Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem. Lett.
1999;9:1171–1174.

[PubMed]
[Google Scholar]

67.
Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Norman BH, Rogier DJ Jr, Zweifel BS, Seibert K. 4,5-diaryloxazole inhibitors of cyclooxygenase-2 (COX-2)


Med. Res. Rev.
1999;19:199–208.

[PubMed]
[Google Scholar]

68.
Velazquez C, Rao PNP, McDonald R, Knaus EE. Synthesis and biological evaluaion of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitors/ nitric oxide donor agents.


Bioorg. Med. Chem.
2005;13:2749–2757.

[PubMed]
[Google Scholar]

69.
Zarghi A, Rao PNP, Knaus EE. Synthesis and biological evaluation of methanesulfonamide analogs of rofecoxib: replacement of methanesulfonyl by methanesulfonamido decrease cyclooxygenase-2 selectivity.


Bioorg. Med. Chem.
2007;15:1056–61.

[PubMed]
[Google Scholar]

70.
Zarghi A, Rao PNP, Knaus EE. Design and synthesis of new rofecoxib analogs as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the methanesulfonylpharmacophore by aN-acetylsulfonamidobioisostere.


J. Pharm. Pharm. Sci.
2007;10:159–67.

[PubMed]
[Google Scholar]

71.
Navidpour L, Shadnia H, Shafaroodi H, Amini M, Dehpour AR, Shafiee A. Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors.


Bioorg. Med. Chem.
2007;15:1976–1982.

[PubMed]
[Google Scholar]

72.
Barta TE, Stealey MA, Collins PW, Weier RM. Antiinflammatory 4,5-diarylimidazoles as selective cyclooxygenase inhibitors.


Bioorg. Med. Chem. Lett.
1998;8:3443–3448.

[PubMed]
[Google Scholar]

73.
Joo YH, Kim JK, Kang SH, Noh MS, Ha JY, Choi JK, Lim KM, Lee CH, Chung S. 2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem. Lett.
2003;13:413–17.

[PubMed]
[Google Scholar]

74.
Zarghi A, Najafnia L, Daraee B, Dadrass OG, Hedayati M. Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.


Bioorg. Med. Chem. Lett.
2007;17:5634–37.

[PubMed]
[Google Scholar]

75.
Zarghi A, Arefi H, Dadrass OG, Torabi S. Design and synthesis of new 2-aryl, 3-benzyl- (1,3-oxazolidine or 1,3-thiazolidine)-4-ones as selective cyclooxygenase (COX-2) inhibitors.


Med. Chem. Res.
2010;19:782–793.

[Google Scholar]

76.
Zarghi A, Arfaei S, Ghodsi R. Design and synthesis of new 2,4,5-triarylimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors.

In press.
[Google Scholar]

77.
Friesen RW, Brideau C, Chan CC, Charleson S, Deschenes D, Dube D, Ethier D, Fortin R, Gauthier JY, Girard Y, Gordon R, Greig GM, Riendeau D, SavoieC , Wang Z, Wong E, Visco D, Xu LJ, Young RN. 2-Pyridinyl-3-(4-methylsulfonyl) phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem. Lett.
1998;8:2777–2782.

[PubMed]
[Google Scholar]

78.
Li CS, Brideau C, Chan CC, Savoie C, Claveau D, Charleson S, Gordon R, Greig G, Gauthier JY, Lau CK, Riendeau D, Therien M, Wong E, Prasit P. Pyridazinones as selective cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem. Lett.
2003;13:597–600.

[PubMed]
[Google Scholar]

79.
Orjales A, Mosquera R, Lopez B, Olivera R, Labeaga L, Nunez MT. Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors.


Bioorg. Med. Chem.
2008;16:2183–2199.

[PubMed]
[Google Scholar]

80.
Singh SK, Saibaba V, Ravikumar V, Rudrawar SV, Daga P, Rao CS, Akhila V, Hegde P, Rao YK. Synthesis and biological evaluation of 2,3-diarylpyrazines and quinoxalines as selective COX-2 inhibitors.


Bioorg. Med. Chem.
2004;12:1881–93.

[PubMed]
[Google Scholar]

81.
Caturla F, Jimenez JM, Godessart N, Amat M, Cardenas A, Soca L, Beleta J, Ryder H, Crespo MI. Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.


J. Med. Chem.
2004;47:3874–86.

[PubMed]
[Google Scholar]

82.
Rao PNP, Uddin M. J and Knaus EE.


Design, synthesis, and structure- activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. J. Med. Chem.
2004;47:3972–3990.

[PubMed]
[Google Scholar]

83.
Zebardast T, Zarghi A, Daraie B, Hedayati M, Dadrass OG. Design and synthesis of 3-alkyl-2-aryl-1,3-thiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.


Bioorg. Med. Chem. Lett.
2009;19:3162–3165.

[PubMed]
[Google Scholar]

84.
Hu W, Guo Z, Chu F, Bai A, Yi X, Cheng G, Li J. Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3- phenyl-indoles: a new series of selective COX-2 inhibitors.


Bioorg. Med. Chem.
2003;11:1153–1160.

[PubMed]
[Google Scholar]

85.
Joo YH, Kim JK, Kang SH, Noh MS, Ha JY, Choi JK, Lim KM, Lee CH, Chung S. 2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem. Lett.
2003;13:413–17.

[PubMed]
[Google Scholar]

86.
Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murty MG, SchwalbDJ , Shumway MJ, Trocha AM, Young DV, Zemtseva IS, Janero DR. 3-[4-Methylsulfonyl)phenyl]-5-(trifluoromethyl) (2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selecselective inhibitors: synthesis and biological evaluation.


J. Med. Chem.
2005;48:3930–3934.

[PubMed]
[Google Scholar]

Baca Juga :   Alat yang mengubah energi listrik menjadi energi kinetik adalah

87.
Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S, Wiseman J. Identification of 2,3-diarylpyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase- 2 inhibitors.


Bioorg. Med. Chem. Lett.
2004;14:5445–48.

[PubMed]
[Google Scholar]

88.
Almansa C, de Arriba AF, Cavalcanti FL, Gomez LA, Miralles A, Merlos M, Garcia-Rafanell J, Forn J. Synthesis and SAR of a new series of COX-2 selective inhibitors: Pyrazolo[1,5-a]pyrimidines.


J. Med. Chem.
2001;44:350–361.

[PubMed]
[Google Scholar]

89.
Baruah B, Dasu K, Vaitilingam B, Vanguri A, Casturi SR, Yeleswarapu KR. 1,2-Diaryl-1-ethanone and pyrazolo[4,3-c]quinoline-4-one as novel selective cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem. Lett.
2004;14:445–448.

[PubMed]
[Google Scholar]

90.
Zarghi A, Zebardast T, Daraie B, Hedayati M. Design and synthesis of new 1,3-benzthiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.


Bioorg. Med. Chem.
2009;17:5369–5373.

[PubMed]
[Google Scholar]

91.
Zarghi A, Reihanfard H, Arfaei S, Daraei B, Hedayati M. Design and synthesis of new 1,2-diaryl-4,5,6,7-tetrahydro-1H-benzo[d]imidazoles as selective cyclooxygenase (COX-2) inhibitors.

In press.
[Google Scholar]

92.
Zarghi A, Ghodsi R, Azizi E, Daraie B, Hedayati M, Dadrass OG. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem.
2009;17:5312–5317.

[PubMed]
[Google Scholar]

93.
Ghodsi R, Zarghi A, Daraei B, Hedayati M. Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem.
2010;18:1029–103.

[PubMed]
[Google Scholar]

94.
Zarghi A, Ghodsi R. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem.
2010;18:5855–5860.

[PubMed]
[Google Scholar]

95.
Murias M, Handler N, Erker T, Pleban K, EckerG , Saiko P, Szekeres T, Jager W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.


Bioorg. Med. Chem.
2004;12:5571–78.

[PubMed]
[Google Scholar]

96.
Uddin MJ, Rao PNP, Rahim MA, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors.


Bioorg. Med. Chem. Lett.
2004;14:4911–4914.

[PubMed]
[Google Scholar]

97.
Uddin MJ, Rao PNP, Knaus EE. Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors.


Bioorg. Med. Chem. Lett.
2004;14:1953–1956.

[PubMed]
[Google Scholar]

98.
Uddin MJ, Rao PNP, Knaus EE. Design and synthesis of (Z)- 1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-1-enes and (Z)- 1-(4- azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesic activity.


Bioorg. Med. Chem.
2005;13:417–24.

[PubMed]
[Google Scholar]

99.
Uddin MJ, Rao PNP, McDonald R, Knaus EE. Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase- 2 (COX-2) isozyme.


Bioorg. Med. Chem. Lett.
2005;15:439–442.

[PubMed]
[Google Scholar]

100.
Chen QH, Rao PNP, Knaus EE. Design, synthesis, and biological evaluation of linear 1-(4-,3- or 2-methylsulfonylphenyl)-2- phenylacetylenes: a novel class of cyclooxygenase inhiobitors.


Bioorg. Med. Chem.
2005;13:6425–6434.

[PubMed]
[Google Scholar]

101.
Tsai WJ, Shiao YJ, Lin SJ, Chiou WF, Lin LC, Yang TH, Teng CM, Wu TS, Yang LM. Selective COX-2 inhibitors: Part 1; synthesis and biological evaluation of phenylazobenzenesulfonamides.


Bioorg. Med. Chem. Lett.
2006;16:4440–4443.

[PubMed]
[Google Scholar]

102.
Lin SJ, TsaiWJ , Chiou WF, Yang TH, Yang LM. Selective COX-2 inhibitors: Part 2; synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethylbenzenesulfonamides.


Bioorg. Med. Chem.
2008;16:2697–706.

[PubMed]
[Google Scholar]

103.
Zarghi A, Arfaee S, Rao PNP, Knaus EE. Design, synthesis and biological evaluation of 1,3-diarylprop-2-en-1-ones: a novel class of cyclooxygenase-2 inhibitors.


Bioorg. Med. Chem.
2006;14:2600–2605.

[PubMed]
[Google Scholar]

104.
Zarghi A, Zebardast T, Hakiminon F, Shirazi FH, Rao PNP, Knaus EE. Synthesis and biological evaluation of 1,3- diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azidopharmacophore as cyclooxygenase-1/-2 inhibitors.


Bioorg. Med. Chem.
2006;14:7044–50.

[PubMed]
[Google Scholar]

105.
Arfaie S, Zarghi A. Design, synthesis and biological evaluation of new (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitors.


Eur. J. Med. Chem.
2010;45:4013–4017.

[PubMed]
[Google Scholar]

106.
Zarghi A, Kakhgi S, Hadipoor A, Daraee B, Dadrass OG, Hedayati M. Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.


Bioorg. Med. Chem. Lett.
2008;18:1336–1339.

[PubMed]
[Google Scholar]

107.
Barnett JW, Dunn JP, Kertesz DJ, Morgans AB, Ramesha CS, Sigal CE, Sjogren EB, Smith DB, Talamas DB.

EP 714895; Chem. Abstr. 125, 142546.
[Google Scholar]

108.
Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.


Br. J. Pharmacol.
2005;144

[PMC free article]
[PubMed]
[Google Scholar]

109.
Kalgutkar AS, Crews BC, Saleh S, Prudhomme D, Marnett LJ. Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors.


Bioorg. Med. Chem.
2005;13:6810–6822.

[PubMed]
[Google Scholar]


Page 2

Biosynthesis of prostanoids

Click on the image to see a larger version.

Salah satu analgetik golongan cox-2 inhibitor adalah

Posted by: pskji.org